On July 14, Insulet Corporation announced a global partnership with Calm, a consumer mental health company, to provide emotional well‑being resources for people living with diabetes, their caregivers, and healthcare professionals. Insulet, known for its Omnipod insulin pump products, framed the collaboration as an extension of its commitment to whole‑person care and reducing the day‑to‑day cognitive burden of diabetes management.
The agreement represents Calm’s first integrated content partnership with a MedTech company and aims to make bespoke mindfulness tools specifically tailored for the diabetes community. According to Insulet, the partnership recognizes the emotional dimension of diabetes and seeks to expand support beyond physical outcomes.
Calm and Insulet launched a bespoke content suite called The Mind in Range Collection. Available on the Calm app and website, the collection is free to access and was created specifically for people affected by diabetes. The announced components include:
The companies describe these tools as practical, brief interventions that can be used by people living with diabetes, caregivers, and clinicians supporting patient well‑being.
Insulet referenced global research indicating substantial unmet mental health and sleep needs among people with diabetes and their caregivers. Reported findings cited in the announcement include:
The announcement also notes that studies of mindfulness‑based stress reduction show meaningful reductions in stress for people with diabetes over time. Insulet and Calm present the collection as a way to normalize conversations about emotional well‑being in routine diabetes care and to make mindfulness resources more widely available.
Manoj Raghunandanan, Insulet’s chief growth officer, emphasized the company’s consumer‑driven approach: “The unmet needs and daily realities of people living with diabetes shape how we innovate and who we choose to partner with.” He framed the partnership as recognizing the emotional strain of diabetes self‑management and as part of Insulet’s goal to “do more for people while asking less of them.” The announcement references global data on burnout among people with diabetes and positions the Calm collaboration as a response to that emotional burden.
Dr. Chris Mosunic, Calm’s Chief Clinical Officer, is quoted highlighting the role of mindfulness in improving quality of life for people with diabetes and the complementarity of Calm’s clinical expertise with Insulet’s diabetes technology leadership. He described the tools as intended to reduce cognitive burden and relieve emotional stress to improve mental wellness.
The Mind in Range Collection is available beginning the date of the announcement on the Calm and Calm Sleep apps, and on Calm’s website. Insulet stated the initiative will roll out globally with bespoke content available on Calm platforms and promoted across Omnipod and Calm channels throughout the year.
To access the announced resources, the source article directs readers to the Omnipod × Calm page at omnipod.com/calm, where the guided meditations, breathing exercise, and Lila Moss’s Sleep Story are posted.
The source article summarizes the partnership announcement and cites Insulet’s global research findings and general statements about related studies on mindfulness‑based stress reduction. The article does not provide detailed methodology, sample sizes, publication references, or dates for the cited research and studies. It also notes that inclusion in the Pharma Friday roundup does not constitute endorsement by Endocrine News or the Endocrine Society.
Readers seeking primary data, peer‑reviewed evidence, or full research reports referenced in the announcement will need to consult Insulet, Calm, or the original study sources for methodology and detailed results, as those specifics were not reported in the article.